

Two Swedish research customers place orders for Lumito's SCIZYS Erbium Kit

Lumito AB (publ) ("Lumito" or the "Company") today announces that two Swedish research customers have placed orders for the Company's SCIZYS Erbium kit. The orders include the use of the Company's Scan-as-a-Service offering and strengthen the Company's position within the research segment. Both customers require the high sensitivity enabled by Lumito's technology.

The first order amounts to approximately SEK 10,000 and comes from a research customer with whom Lumito has previously collaborated. Within the scope of the earlier collaboration, the customer had the opportunity to evaluate the technology and is satisfied with the results. This has now led to a repeat purchase to enable continued research and further development of the project. The customer's application places high demands on sensitivity, including the ability to analyse and identify rare cells.

The second order relates to a pilot study with an initial order value of approximately SEK 10,000-20,000, with the potential for additional revenue depending on the scope of future scanning. The dialogue with the customer has been ongoing since the third quarter of 2025, and the customer has now chosen to move forward by placing an order for a SCIZYS Erbium kit. As part of the pilot study, a limited number of initial scans are offered, after which the customer will transition to using Lumito's Scan-as-a-Service offering. This project is also driven by the need for higher sensitivity than what established analytical methods can provide.

"That two additional Swedish research customers are now choosing to use our technology, one of them a returning customer, is a clear validation of the value of SCIZYS and our ability to meet needs where high sensitivity is critical. Scan-as-a-Service is an effective way for customers to get started with the technology and at the same time an important tool in our commercial development. Although the initial order values are limited, we see great potential in long-term collaborations and recurring revenue", says Sanna Wallenborg, CEO of Lumito.

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Two Swedish research customers place orders for Lumito's SCIZYS Erbium Kit](#)